Announced today: Skye $SKYE and @RedxPharma will combine as Nasdaq-listed Fibrx Therapeutics. Lead program RXC008 is a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease, with Phase 2 topline expected H2 2028. More: ir.skyebioscience.com/compan…
Skye Bioscience announced the opening of Cohort 2 in the CBeyond Part C Expansion Study after favorable safety data from the first four participants treated in Cohort 1.
The progression into Cohort 2 marks an important step forward as the study continues evaluating nimacimab as a potential treatment for obesity and metabolic health. The company remains on track to report topline data from the expansion study in Q4 2026.
Read more: ir.skyebioscience.com/news-r…
#Biotech #Obesity #ClinicalDevelopment
2
3
774
Skye Bioscience reported first quarter 2026 financial results and business updates as the company advances nimacimab in obesity.
During the quarter, Skye initiated Part C of the CBeyond™ Expansion Study and advanced activities supporting a Phase 2b-ready program. This included ENHANZE compatibility work for high-volume subcutaneous delivery and engagement with Lilly Catalyze360-ExploR&D on target product profile and trial design strategy.
The company remains on track to report topline CBeyond Expansion Study data in Q4 2026.
Read the full update: ir.skyebioscience.com/news-r…
#biotech #obesity #clinicaldevelopment
2
2
311
In 2026, Skye is focused on defining the optimal dose and development path for nimacimab as a differentiated add-on to GLP-1 therapies like semaglutide.
Our priorities:
• Generate higher-dose safety and PK data
• Enable a practical subcutaneous dosing approach
• Finalize a Phase 2b study with regulatory alignment
The goal is to expand what GLP-1s can achieve for patients who need more.
Learn more: ir.skyebioscience.com/
#Biotech #Obesity #ClinicalDevelopment
1
591
Skye Bioscience will be presenting at the upcoming GLP-1-Based Therapeutics Summit, a leading forum focused on advancing next-generation therapies in obesity and metabolic disease.
We look forward to engaging with the scientific and clinical community as we continue to advance our development programs and explore new approaches to improving metabolic health.
Learn more: ir.skyebioscience.com/news-r…
#Biotech #Obesity #ClinicalDevelopment
1
258
We are taking the next step to better understand nimacimab’s full potential.
Skye has initiated an expansion of the CBeyond study to evaluate higher doses, building on earlier findings in combination with semaglutide.
The goal is to better define the dose-efficacy relationship, confirm safety at higher exposure levels, and inform Phase 2b dose selection.
Learn more: ir.skyebioscience.com/
#Biotech #Obesity #ClinicalDevelopment
2
212
Skye continues to build on its focused approach to optimizing dose and exposure of nimacimab. We recently treated the first patient in our higher-dose CBeyond Expansion Study, designed to evaluate the relationship between exposure and safety and inform Phase 2b dose selection.
Read the release: ir.skyebioscience.com/news-r…
#Biotech #Obesity #ClinicalDevelopment
Skye is advancing nimacimab with a clear focus: Optimizing dose and exposure to unlock its full potential. In our CBeyond study, nimacimab demonstrated results in combination with semaglutide. Higher exposure may be needed to engage peripheral CB1 targets. Learn more: ir.skyebioscience.com/
#Biotech #Obesity #ClinicalDevelopment
2
205
Skye continues to advance nimacimab as a potential differentiated therapy for obesity. Progress includes initiating the CBeyond Expansion Study and implement FDA feedback to guide Phase 2b planning.
Read more at: ir.skyebioscience.com/news-r…
#Biotech #Obesity #ClinicalDevelopment
5
229
Today, Skye reported its financial results for the fourth quarter and full year ended December 31, 2025 while also sharing a business update highlighting recent achievements and important milestones ahead.
Read the release: ir.skyebioscience.com/news-r…
#Biotech #Obesity #ClinicalDevelopment










